Age-Related Macular Degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to a blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Abnormal new blood vessels sometimes grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. The increasing number of aging people can define other reasons for the rising rise of procedures and requirements for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-age-related-macular-degeneration-amd-disease-anti-vegf-market
Data Bridge Market Research analyzes that the Global Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market is expected to grow at a CAGR of 6.8% in the forecast period of 2024 to 2031 and is expected to reach USD 22,951.90 million by 2031.
Key Findings of the Study
Rising Prevalence of Age-Related Macular Degeneration
The prevalence of vision-threatening diseases, such as glaucoma, cataracts, and age-related macular degeneration, is expected to increase in developed countries due to the aging population and rising life expectancy. They stand out as the leading cause of blindness in the western working-age population. It is estimated that nearly 60% of patients have severe visual impairment occurring disease shortly after birth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Regeneron Pharmaceuticals Inc. (U.S.), Biogen (U.S.), Outlook Therapeutics, Inc. (U.S.), Sulentis, S.A. (Spain), Novartis AG (Switzerland), Genentech, Inc. (U.S.), Bayer AG (Germany), Adverum Biotechnologies, Inc. (U.S.), Gensight Biologics (France), REGENXBIO INC. (U.S.), OCUGEN, INC. (U.S.), MeiraGTX, Limited (U.S.), Johnson & Johnson Services, Inc. (U.S.), IVERIC bio, Inc. (U.S.), An Astellas Company (U.S), KODIAK SCIENCES INC. (U.S.), and lonis Pharmaceuticals (U.S.), among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, and regulatory framework.
|
Segment Analysis
The global Age-Related Macular Degeneration (AMD) disease - anti VEGF market is segmented into three notable segments on the basis of type, end user, and distribution channel.
- On the basis of type, the market is segmented into dry AMD and wet AMD
In 2024, the wet AMD is expected to dominate the global Age-Related Macular Degeneration (AMD) disease - anti VEGF market
In 2024, the wet AMD segment is expected to dominate the market with the market share of 90.93% due to the increasing geriatric population and the introduction of novel treatment methods for wet AMD coupled with a growing number of clinical trials focused on wet AMD.
- On the basis of end user, the market is segmented into hospitals, specialty clinics, Ambulatory Surgical Centers, home healthcare, and others. In 2024, the hospitals segment is expected to dominate the market with a market share of 46.02%.
- On the basis of distribution channel, the market is segmented into direct tender and retail sales
In 2024, the retail sales segment is expected to dominate the global Age-Related Macular Degeneration (AMD) disease - anti VEGF market
In 2024, the retail sales segment is expected to dominate the market with a market share of 62.12% as they are the primary source of procurement of diagnostic and surgical devices and therapies by healthcare organizations.
Major Players
Data Bridge Market Research analyzes Regeneron Pharmaceuticals Inc. (U.S.) Novartis AG (Switzerland), Bayer AG (Germany), IVERIC bio (A Subsidiary of Astellas Pharma Inc.) (U.S.), and Genentech, Inc. (A subsidiary of F. Hoffmann-La Roche Ltd ) (U.S.) as the major market players of the global Age-Related Macular Degeneration (AMD) disease - anti VEGF market.
Market Development
- In November 2023, Regeneron Pharmaceuticals, Inc. announced long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg at the American Academy of Ophthalmology (AAO) annual meeting in San Francisco. This is an investor event where the companies try to attract investors, which helps the company increase the R&D
- In August 2023, Astellas Pharma Inc. announced that IZERVAY (avacincaptad pegol intravitreal solution) will be approved by the U.S. Food and Drug Administration (FDA) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The rate of GA progression at the 12-month primary endpoint was statistically significantly (p<0.01) lower in two Phase 3 clinical trials with the novel complement C5 inhibitor IZERVAY, making it the only approved treatment for GA
- In November 2022, Sylentis, S.A., announced the recruitment of the first patient in a new phase II dose-finding trial with its compound SYL1801 for treating patients with Neovascular Age-Related Macular Degeneration (AMD). This is a randomized, double-blind, phase II trial with three parallel groups in which different dose levels will be administered to each group of subjects. The study has already started and will recruit 90 patients in different centers in several European countries. The trial's primary objective is to evaluate the effect on visual acuity of SYL1801 at all three doses, administered as one drop daily for six weeks in patients with neovascular AMD
- In May 2022, Adverum Biotechnologies, Inc. announced that the company had presented data at the American Society of Gene and Cell Therapy (ASGCT) 2022 annual meeting on the efficacy and safety outcome of ADVM-022 that supported Phase 2 development plans. This results in evaluating the ADVM-022 dose with new enhanced prophylactic steroid regimens in the subsequent clinical trial
- In March 2022, Novartis AG announced that Beovu (brolucizumab) 6 mg had been authorized by the European Commission (EC) to treat visual impairment caused by Diabetic Macular Edoema (DME). Beovu was initially approved by the EC in 20203 to treat wet age-related macular degeneration; the DME indication marks the medication's second approval. The ruling of the European Community (EC) applies to all 27 EU members and Liechtenstein, Iceland, and Norway
Regional Analysis
Geographically, the countries covered in the global Age-Related Macular Degeneration (AMD) disease - anti VEGF market report are the U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Saudi Arabia, Israel, U.A.E., Kuwait, and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global Age-Related Macular Degeneration (AMD) disease - anti VEGF market
North America is expected to dominate the market owing to the higher level of investments by the U.S. manufacturers and the increasing advancement in the treatment options in the U.S.
Asia-Pacific is estimated to be the fastest-growing region in the global Age-Related Macular Degeneration (AMD) disease - anti VEGF market
Asia-Pacific is expected to grow during the forecast period due to the rapid development of medical facilities in emerging economies in this region. In addition, the rising level of healthcare expenditure and increasing per-capita income are expected to propel the market growth in this region.
For more detailed information about the global Age-Related Macular Degeneration (AMD) disease - anti VEGF market report, click here – https://www.databridgemarketresearch.com/reports/global-age-related-macular-degeneration-amd-disease-anti-vegf-market
